Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

30.50
-0.3900-1.26%
Post-market: 31.110.6100+2.00%19:32 EDT
Volume:631.27K
Turnover:19.25M
Market Cap:1.97B
PE:-9.15
High:32.12
Open:31.46
Low:29.98
Close:30.89
52wk High:40.22
52wk Low:18.80
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.67
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:5.70
PE(LYR):-262.34

Loading ...

Stoke Therapeutics Q2 FY26 Net Loss Widens to $61.62 Million; Revenue Falls to $9.33 Million

Reuters
·
Aug 04

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Q2 EPS USD -0.93

THOMSON REUTERS
·
Aug 04

Press Release: Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Dow Jones
·
Jul 28

Stoke Therapeutics Schedules Webcast, Call on Q2 Business and Financial Update

Reuters
·
Jul 28

Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?

Simply Wall St.
·
Jul 22

Stoke Therapeutics Chief Scientific Officer Thomas Mccauley Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Stoke Therapeutics Grants CSO Mccauley Options for 225,000 Shares at $29.91 Each

Reuters
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jul 14

Stoke Therapeutics Names Thomas Mccauley Chief Scientific Officer

Reuters
·
Jul 13

Stoke Therapeutics Appoints Thomas Mccauley, Ph.d., as Chief Scientific Officer

THOMSON REUTERS
·
Jul 13

Stoke Therapeutics Initiated at Buy by Goldman Sachs

Dow Jones
·
Jul 13

Stoke Therapeutics initiated with a Buy at Goldman Sachs

TIPRANKS
·
Jul 13

Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

Simply Wall St.
·
Jul 10

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)

TIPRANKS
·
Jul 09

Stoke Therapeutics CMO Barry Ticho Disposes of Common Shares Worth $235,889.32

Reuters
·
Jul 07

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 06

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Reuters
·
Jul 06

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 02

Stoke Therapeutics Completes Enrollment in Phase 3 Emperor Trial of Dravet Drug Zorevunersen

Reuters
·
Jun 30